Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) rose 4.1% during mid-day trading on Thursday . The company traded as high as $13.55 and last traded at $13.48, with a volume of 153,470 shares changing hands. The stock had previously closed at $12.95.

ADMS has been the topic of a number of analyst reports. Credit Suisse Group AG reissued a “buy” rating and set a $21.00 target price on shares of Adamas Pharmaceuticals in a report on Monday, July 25th. Mizuho raised shares of Adamas Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $22.00 target price on the stock in a report on Thursday, June 16th. Piper Jaffray Cos. reissued an “overweight” rating and set a $44.00 target price on shares of Adamas Pharmaceuticals in a report on Tuesday, June 14th. Zacks Investment Research cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Noble Financial initiated coverage on shares of Adamas Pharmaceuticals in a report on Friday, June 17th. They set a “buy” rating and a $25.00 target price on the stock. Two analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company. Adamas Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $32.00.

The firm has a 50-day moving average of $14.91 and a 200-day moving average of $15.51. The stock’s market cap is $296.04 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.76) by $0.11. Equities analysts expect that Adamas Pharmaceuticals Inc. will post ($3.10) EPS for the current year.

A hedge fund recently raised its stake in Adamas Pharmaceuticals stock. Russell Frank Co increased its stake in Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 119.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 83,773 shares of the specialty pharmaceutical company’s stock after buying an additional 45,652 shares during the period. Russell Frank Co owned 0.45% of Adamas Pharmaceuticals worth $2,395,000 as of its most recent SEC filing.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.